ProKidney (PROK) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
REGENXBIO (RGNX) has outperformed ProKidney (PROK) over the past year, losing 27.7% versus a loss of 47.0%. Over five years, RGNX leads with a -78.9% price change compared with -84.1% for PROK. ProKidney is the larger company by market cap ($626.7 million vs $501.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | RGNX |
|---|---|---|
| Share price | $1.57 | $7.60 |
| Market cap | $626.72M | $501.37M |
| 1-day change | -1.88% | +1.95% |
| YTD return | -29.91% | -47.26% |
| 1-year return | -46.96% | -27.74% |
| 5-year return | -84.09% | -78.87% |
| EPS (TTM) | $-0.55 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.48 | $16.19 |
| 52-week low | $1.30 | $5.46 |
| Distance from 52-week high | -54.89% | -53.09% |
| Analyst consensus | none | buy |
| Avg. price target upside | +298.09% | +210.47% |
| Average volume | 1.30M | 1.52M |
| Shares outstanding | 208.93M | 66.01M |
| Employees | 231 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RGNX has outperformed PROK by 19.2 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
PROK vs RGNX FAQ
Which is bigger, ProKidney or REGENXBIO?
ProKidney (PROK) is larger, with a market capitalization of $626.72M compared with $501.37M for REGENXBIO (RGNX).
Which stock has performed better over the past year, PROK or RGNX?
RGNX returned -27.74% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.